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Next-generation sequencing (NGS) has enabled genome-wide personalized oncology efforts at centers and
companies with the specialty expertise and infrastructure required to identify and prioritize actionable variants.
Such approaches are not scalable, preventing widespread adoption. Likewise, most targeted NGS approaches fail
to assess key relevant genomic alteration classes. To address these challenges, we predefined the catalog of
relevant solid tumor somatic genome variants (gain-of-function or loss-of-function mutations, high-level copy
number alterations, and gene fusions) through comprehensive bioinformatics analysis of >700,000 samples. To
detect these variants, we developed the Oncomine Comprehensive Panel (OCP), an integrative NGS-based assay
[compatible with b20 ng of DNA/RNA from formalin-fixed paraffin-embedded (FFPE) tissues], coupled with an
informatics pipeline to specifically identify relevant predefined variants and created a knowledge base of related
potential treatments, current practice guidelines, and open clinical trials. We validated OCP using molecular
standards and more than 300 FFPE tumor samples, achieving >95% accuracy for KRAS, epidermal growth factor
receptor, and BRAF mutation detection as well as for ALK and TMPRSS2:ERG gene fusions. Associating positive
variants with potential targeted treatments demonstrated that 6% to 42% of profiled samples (depending on
cancer type) harbored alterations beyond routine molecular testing that were associated with approved or
guideline-referenced therapies. As a translational research tool, OCP identified adaptive CTNNB1 amplifications/
mutations in treated prostate cancers. Through predefining somatic variants in solid tumors and compiling
associated potential treatment strategies, OCP represents a simplified, broadly applicable targeted NGS system
with the potential to advance precision oncology efforts.
Neoplasia (2015) 17, 385–399Introduction
Precision medicine approaches, where patients are treated with
therapies directed against the specific molecular alterations driving
their tumors, have revolutionized oncology [1–4]. Such approaches
require identification of driving molecular alterations (which may
occur only in a subset of a given histologic cancer type or in cancers
arising from diverse organs), development of targeted therapies, and
diagnostic tests to identify appropriate patient populations for clinical
trials and eventual implementation [5–7]. The early successes of
trastuzumab (a monoclonal antibody against ERBB2) in the subset of
breast adenocarcinomas with ERBB2 amplifications [8], and imatinib
(an ABL kinase inhibitor) in the subset of leukemia driven by
BCR-ABL gene fusions (chronic myeloid leukemia) [9], have been
replicated in numerous cancers [1–4]. For example, multiplexed
assessment of driving somatic alterations in lung cancer has been
shown to aid in physician selection of therapy, and patients with
drivers receiving a matched therapy lived significantly longer than
those not receiving a matched therapy [10].
Recent advances in genome sciences, including next-generation
sequencing (NGS), have led to the identification of hundreds of
recurrent somatically altered genes through the analysis of tens of
thousands of cancer samples from individual investigators and large
consortia, such as The Cancer Genome Atlas (TCGA) [11–15].
These technological advances are also changing routine molecular
pathology practice from single gene–based tests (i.e., Sanger
sequencing to assess (epidermal growth factor receptor) EGFR
mutations in lung adenocarcinoma) to multiplexed NGS assays.Several NGS approaches have been successfully clinically implement-
ed in oncology, including multiplexed polymerase chain reaction
(PCR)–based panels assessing tens to hundreds of genes, hybrid
capture–based panels targeting hundreds of genes, as well as
comprehensive exome/genome/transcriptome sequencing [16–26].
These approaches vary in sample requirements, nucleic acids assessed,
cost, throughput, genes and alteration types assessed, and perfor-
mance. For example, most clinically implemented multiplexed
PCR-based approaches fail to assess copy number alterations
(CNAs) and/or gene fusions [16,19,22,25], which guide current
treatment selection for several cancers.
The primary challenge with comprehensive NGS approaches,
however, is the specialty infrastructure and expertise needed to interpret
the results and convey treatment strategies to clinicians. Several centers
using comprehensive NGS-based oncology approaches require
NGS-based tumor boards [21] to guide interpretation and inform
clinical decision-making. Large companies have also been established
with the goal of providing comprehensive NGS-based precision
oncology services [18]; however, interpretation of results and prioritizing
treatment strategiesmay still be outsourced. Scalability limitations hinder
widespread adoption of such initiatives in reference laboratories.
To enable precision medicine approaches for all patients with
cancer, rapid, inexpensive, scalable NGS solutions capable of assessing
all classes of current and near-term clinically relevant targets [point
mutations, short insertions/deletions (indels), CNAs, and gene
fusions] from routine formalin-fixed paraffin-embedded (FFPE)
tissues are required. Such a technical solution must be coupled with
Neoplasia Vol. 17, No. 4, 2015 Scalable NGS system for precision oncology Hovelson et al. 387a dynamic, scalable, analytical approach capable of prioritizing
treatment options. To begin to address these challenges, we report the
development and validation of the Oncomine Comprehensive Panel
(OCP), a multiplexed PCR-based NGS assay and analytical system to
identify and prioritize potential treatment strategies from predefined
somatic solid tumor genome variants. The OCP is compatible with 20
ng of FFPE isolated DNA and 15 ng of FFPE isolated RNA and
benchtop Ion Torrent sequencers. Demonstrating the potential for a
scalable solution to enable widespread precision medicine oncology
applications, the OCP will be used in the National Cancer Institute
(NCI) Match Trial to assess 3000 cancer samples for trial selection in a
multi-arm umbrella study with sequencing conducted at multiple sites.
Materials and Methods
Analysis of Relevant Somatic Variants in Solid Tumors
The OCP was designed to interrogate somatic mutations, CNAs,
and gene fusions involving oncogenes and tumor suppressors
recurrently altered in solid tumors with the potential for near-term
clinical relevance. To define OCP content, we used evidence-based
analysis of genomic alterations present in Oncomine, a resource
composed of mutation, copy number, and gene fusion data from
N700,000 cell line, xenograft, and clinical cancer samples as of
December 2013 [27–29]. Candidate genes with somatic driver
mutations were derived from gain-of-function (GoF) and loss-of-
function (LoF) analyses performed on 686,530 tumor samples with
mutation data in Oncomine. Candidate driver CNA events were
identified by performing a minimal common region (MCR)
assessment on a pan-cancer subset of 10,249 tumor samples in
Oncomine [28]. In addition, single cancer–type assessments were
performed to identify private candidate copy number drivers.
Candidate driver gene fusions were identified from the Mitelman
Database of Chromosome Aberrations and Gene Fusions in Cancer
(http://cgap.nci.nih.gov/Chromosomes/Mitelman) as well as from
analyzing 6438 primary tumor sample RNA-seq profiles contained
within Oncomine. Complete details on somatic variant analysis to
define candidates are provided in the Supplementary Materials. All
candidate driver GoF, LoF, and CNA genes, as well as gene fusions,
were then assessed for evidence of near-term potential clinical
relevance as defined in the Supplementary Materials.
OCP NGS Assay Design
We developed multiplexed PCR (Ion AmpliSeq) NGS panels to
characterize DNA (mutations and CNAs) and RNA (gene fusions)
based alterations. For GoF alterations, amplicons were designed to
assess recurrent hotspots as defined above. For LoF alterations,
amplicons were designed to tile the gene's entire coding sequence. For
CNAs, sufficient amplicons (n = 3 to 38) were designed from coding
and noncoding regions to facilitate copy number profiling. For the
RNA-based panel, primers were included to detect known gene
fusion junctions, assess the 5′ and 3′ regions of RET, ROS1, and
ALK (to enable testing for fusions involving novel 5′ fusion partners
through 3′/5′ expression imbalance), and quantify housekeeping/
positive expression genes (HMBS, ITGB7, LMNA, MYC, and TBP);
a small subset of the prostate cancer samples (n = 12) was sequenced
using a version of the RNA panel that did not contain the 3′/5′
expression imbalance assays. AmpliSeq panels were designed using
AmpliSeq Designer, and multiplexed pools were obtained from Ion
Torrent. Two versions of both the DNA- and RNA-based panels wereassessed herein during iterative optimization, and complete informa-
tion on the panels is provided in Table S1.
Molecular Standards
We used two commercially available molecular standards to assess
performance of the DNA component of the OCP. The AcroMetrix
Oncology Hotspot Control (AOHC; Life Technologies, Foster City,
CA) was designed to assess somatic mutation detection performance
by NGS assays. The custom version used herein contained 365
applicable single/multiple nucleotide variants (SNVs/MNVs) and 33
indels each at an estimated allele frequency of 0.20 on the GM24385
cell line genomic background. AOHC DNA was used directly for
library preparation.
The Quantitative Multiplex Reference Standard (QMRS; Horizon
Diagnostics, Cambridge, United Kingdom) consists of one to three
FFPE tissue sections from multiplexed FFPE cell lines with a known
set of 30 engineered and endogenous mutations present at specific
variant allele frequencies quantified by droplet digital PCR. Of the 30
mutations, 16 (all 11 primary engineered mutations and 5 of 19
secondary endogenous mutations) were targeted by the OCP and
were used for evaluation. QMRS tissue was processed as for the
remaining tissue cohorts for DNA isolation and library preparation.
Tissue Cohorts
We used three cohorts of routine FFPE tissues for OCP evaluation
[molecular (MO), lung (LU), and prostate (PR)]. All FFPE specimens
were obtained from the University of Michigan Department of
Pathology Tissue Archive with Institutional Review Board (IRB)
approval. Diagnostic hematoxylin and eosin–stained slides were
reviewed by board-certified anatomic pathologists (A.S.M. and S.A.T.).
The MO cohort consisted of all cancer specimens (including
biopsy, resection, and cell block specimens) sent during a 5-month
period to the Clinical Laboratories Improvement Amendments–
certified University of Michigan Molecular Oncology/Genetics
Laboratory for 1) EGFR, BRAF, or KRAS mutation testing or 2)
ALK rearrangement testing. Complete details of the MO cohort
and clinicopathologic information for all cases are provided in the
Supplementary Materials and Table S2. The LU and PR cohorts
consisted of 104 and 118 retrospectively identified FFPE tissue
specimens, respectively. A subset of the PR samples (n = 37) has been
previously assessed by a combined capture-based NGS (Agilent
Haloplex followed by Ion Torrent NGS) and TaqMan low-density
array quantitative reverse transcription–PCR (qRT-PCR) panel [30].
Clinicopathologic information for all included cases in the LU and
PR cohorts is provided in Tables S3 and S4. Targeted NGS of all
tumor tissues was performed with IRB approval.
Nucleic Acid Isolation
For each specimen, 3 × 10 to 10 × 10 μm FFPE sections were cut
from a single representative block per case, using macrodissection
with a scalpel as needed to enrich the tumor content. DNA and RNA
were isolated using the Qiagen AllPrep FFPE DNA/RNA Kit
(Qiagen, Valencia, CA) as described [31]. DNA and RNA were
quantified using the Qubit 2.0 fluorometer (Life Technologies).
DNA/RNA Libraries
DNA/RNA libraries were generated essentially as described
[31,32]. DNA libraries were generated from 20 ng of DNA per
sample using the Ion AmpliSeq Library Kit 2.0 (Life Technologies)
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instructions with barcode incorporation. RNA libraries were generated
from 15 ng of RNA per sample using the Ion AmpliSeq RNA Library
Kit. OCP AmpliSeq libraries were quantified using the Ion Library
Quantification Kit according to the manufacturer’s instructions.
Template Generation and Sequencing
Templates for DNA and RNA libraries were prepared using the
Ion Personal Genome Machine (PGM) Template OT2 200 Kit (Life
Technologies) on the Ion One Touch 2 according to the
manufacturer’s instructions. Sequencing of multiplexed templates
was performed using the Ion Torrent PGM on Ion 318 chips using
the Ion PGM Sequencing 200 Kit v2 (Life Technologies) according
to the manufacturer’s instructions. For the LU and PR cohorts, a
single DNA template and four to eight RNA templates were assessed
separately on a single 318 chip. For the MO cohort, a single DNA
template was combined with a single RNA template in a 4:1 ratio and
assessed on a single 318 chip. For experiments with molecular
standards, single DNA templates were assessed on one 318 chip.
Data Analysis
Data analysis was performed using Torrent Suite (4.2.0) and the
Coverage Analysis (or Coverage Analysis RNA) plug-ins (both
v4.0-r73765), along with the Ion Reporter (4.2.0) Fusion analysis
workflow essentially as described [31,32]. For DNA sequencing
(DNA-seq), alignment was performed using TMAP with default
parameters, and variant calling was performed using the Torrent
Variant Caller (TVC) plug-in (version 4.2-8-r87740) using default
low-stringency somatic variant settings. Somatic variant identification
was performed essentially as described [31,33] using read and base
level filtering, which we have previously confirmed to identify variants
that pass Sanger sequencing validation with N95% accuracy. Copy
number analysis from total amplicon read counts provided by the
Coverage Analysis plug-in was performed essentially as described
[19,31,32]. As an estimate of data quality, we determined the SD of
the amplicon-level copy number estimates relative to the gene-level
estimate for each gene per sample (Figure S1). Gene fusion analysis
was performed within the Ion Reporter (4.2.0) Fusion analysis
workflow, with reads from the RNA AmpliSeq panel aligned using
TMAP to a gene reference of targeted chimeric fusion transcripts as
well as reference sequences for expression imbalance and expression
control gene targets. Complete description of all data analyses is
provided in the Supplementary Materials.
Alteration Prioritization and Potential Actionability Assessment
Somatic SNVs/indels passing filtering in a GoF gene were considered
GoF if occurring at the predefined hotspot residue targeted in OCP.
Somatic variants in an LoF gene were considered LoF if deleterious
(nonsense or frame shifting) or occurring at a predefined hotspot
residue. Somatic CNAs were considered for potential actionability
analysis if they were concordant with the predicted alteration
(amplification or deletion) from Oncomine analysis as described
above. Somatic gene fusions were considered for actionability analysis if
they represented known gene fusions from the Mitelman database or
Oncomine analysis or involved known 3′ or 5′ drivers with novel
partners (i.e., ERC1-BRAF fusion in MO-17, with recurrent fusions
involving BRAF as a 3′ partner reported previously [34]).
These prioritized variants were then associated with potential
actionability using the Oncomine database. Briefly, for each patient,the “most actionable” alteration was identified by prioritizing 1)
variants referenced in Food and Drug Administration (FDA) drug
labels, 2) variants referenced in National Comprehensive Cancer
Network (NCCN) treatment guidelines in the patient’s cancer type,
3) variants referenced in an NCCN guideline in another cancer type,
and 4) variants referenced as inclusion criteria in a clinical trial.
Actionable variants were identified by manual curation of FDA labels
and NCCN guidelines and by keyword searches and manual curation
of clinical trial records in the TrialTrove database. Alterations
associated with specific treatments are shown in Table S5.
qRT-PCR and Immunohistochemistry Validation
Details of qRT-PCR validation of ERC1:BRAF and TPR:NTRK1
fusions as well as ERBB2 immunohistochemistry (IHC) to confirm
copy number gains are provided in the Supplementary Materials and
Table S6.
Statistical Tests. All statistical tests were performed inR (3.1.0) using
two-sided tests. P values b .05 were considered statistically significant.
Results
OCP Development
To define relevant somatic cancer genome variants based on
near-term potential actionability, we first interrogated data from
N700,000 tumor samples in the Oncomine database (including
N8000 exomes, N7000 transcriptomes, and N30,000 copy number
profiles in addition to tumors studied by single gene/targeted
approaches) to identify pan-cancer, recurrently altered oncogenes
(enriched in GoF hotspot mutations), tumor suppressors (enriched in
LoF deleterious mutations), genes targeted by high-level amplifica-
tions or deletions, and driving gene fusions (Figure 1A). Genes with
these variants were then filtered based on near-term potential
actionability (see Materials and Methods section). The distribution of
these variants across N7000 TCGA samples from 23 cancer types is
shown in Figure 1B.
To translate the relevant somatic cancer genome to an NGS assay
capable of detecting mutations, CNAs, and gene fusions (including
multiple splice isoforms) but compatible with limited amounts of
routine FFPE tissues, we developed custom Ion Torrent multiplexed
PCR-based DNA-seq and RNA sequencing (RNA-seq) panels,
together comprising the OCP, as shown in Figure 1C. In total, the
final OCP version assessed herein (v0.9b) interrogates 143 unique
cancer genes including 73 oncogenes, 49 CNA genes, 26 tumor
suppressor genes, and 22 fusion driver genes. The targeted DNA-seq
panel includes 2530 amplicons covering 260,717 base pairs in 130
different genes. To minimize panel size and focus on predefined
relevant alterations, only GoF mutations were targeted in oncogenes,
while high-level CNA genes were targeted by 3 to 38 probes to
facilitate copy number profiling [19] and the entire coding sequence
of tumor suppressors were targeted to identify LoF mutations and
GoF mutations. The targeted RNA-seq panel included a total of 154
primer pairs targeting known gene fusion isoforms (n = 148) as well as
5′ and 3′ expression assays for RET, ROS1, and ALK to enable novel
fusion discovery through 3′/5′ expression imbalance ratios. To enable
appropriate normalization in downstream analyses, the targeted
RNA-seq panel also includes five additional primer pairs targeting a
pre-determined set of housekeeping/positive expression genes
(HMBS, ITGB7, LMNA, MYC, and TBP). Details of the two
versions of the OCP panel (v0.9a and v0.9b) validated and applied
herein are presented in Table S1.
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Figure 1. Pan-solid tumor cancer somatic alteration analysis to identify relevant variants. (A) Using the Oncomine database supplemented
with data from COSMIC, more than 700,000 tumor samples (including N8000 cancer exomes) were used to assess genes for
overrepresentation of hotspot (GoF) and deleterious (LoF)mutations to identify oncogenes and tumor suppressors, respectively. Array-based
copy number profiles from N30,000 tumors were assessed byMCR analysis to identify targets of focal, high-level amplifications or deletions.
Transcriptomes from N7000 cancers were similarly assessed for driver gene fusions. Prioritized genes were further filtered to include only
near-term relevant alterations for inclusion into the OCP. (B) Frequency of somatic alterations (type according to color in the legend) in OCP
included genes across publically available TCGA data. For each gene per cancer type, alteration frequency (b0.01 to N0.20) is indicated by the
size of the circle according to the legend. Selected genes of interest are highlighted. (C) The OCPwas designed for compatibility with routine
FFPE tissues,with co-isolation ofDNA/RNA fromFFPE tissues used inour validation. TheOCPconsists ofmultiplexedPCR (AmpliSeq) panels
compatible with 20 ng of DNA and 15 ng of RNA, which can be combined after library generation for NGS on Ion Torrent benchtop
sequencers. By predefining relevant somatic variants, identified variants can be linked to potential treatment strategies.
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To validate OCP performance, we first assessed the DNA
component using the AOHC molecular standard, a cell line DNA
sample engineered to contain 398 OCP targeted variants at 0.20expected variant allele frequencies. OCP detected 364 of 365 (99.7%)
targeted SNVs/MNVs, with a median variant allele frequency of 0.24
(interquartile range 0.21-0.28) as shown in Figure S2 and Table S7.
Of the 33 OCP targeted indels, we detected 25 (75.8%) at a median
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and Table S7). Of the eight indels that were not detected, three were
over 10 bases in length (12, 30, 41 bases) and five were single nucleotide
insertions or deletions occurring within two to seven base homopolymer
runs. Accurate indel identification in homopolymer runs is a known
challenge with current Ion Torrent sequencing technology [16].
We also profiled DNA isolated from commercially available FFPE
sections containing a cell line mixture (QMRS cell line) with
engineered and endogenous mutations at precise variant frequencies.
In total, 16 known mutations in the QMRS cell line (11 primary
induced and 5 endogenous mutations; median variant allele
frequency 0.10, range 0.01-0.33) are targeted by the OCP. To
prioritize high-quality somatic variants, we applied our standard
filtering approach (which includes filters at b5% or b10% depending
on alteration type; see Materials and Methods section) to default
variant calls. Ten of 16 (63%) OCP-targeted mutations (including 8/
11 induced and 2/5 endogenous) were called by the TVC using our
standard approach at variant allele frequencies highly correlated with
those expected (r2 = 0.99; Table S8). Five of the remaining six (83%)
OCP-targeted mutations were detectable at close-to-expected
frequencies—including indels and point mutations at b1% to 5%
variant allele frequencies—through automated variant calling (Table
S8). The only variant not detected by OCP was a secondary NF1
frameshift deletion at the start of a 6-bp homopolymer run (expected
frequency of 7.5%); hence, in total, 15 of 16 (94%) of OCP-targeted
known mutations in the QMRS cell line were detected through our
automated variant calling procedures (Table S8). Highly concordant
results were observed with both OCP versions, as well as separate Ion
Torrent PGM template preparation and sequencing runs performed
at two locations (Ann Arbor, MI and Carlsbad, CA) from aliquots of
the same DNA library (Table S8).
OCP Performance in FFPE Tumor Tissue Cohorts
To validate performance and demonstrate applicability, we applied
the OCP to three cohorts of routine FFPE tissue specimens: a cohort
composed of tumor samples sent for routine molecular diagnostics (MO
cohort, n = 105 samples) and retrospective lung cancer (LU, n = 104
samples) and prostate cancer (PR, n = 118 samples) cohorts. For each
cohort, 3 × 10 to 10 × 10 μm FFPE sections were used for DNA/RNAFigure 2. Validation of the OCP using an oncology cohort undergo
prospectively identified cohort of FFPE cancer samples undergoingm
EGFR, or ALK rearrangements (MO cohort). All OCP-defined relevant a
OCP for the 104 informative samples are shown in the heat map. Spe
SNV = nonsynonymous SNV; Fs and Fp indel = frame-shifting and
alterations. Samples not sequenced in OCP RNA analysis are indicat
due to noisy profiles are shown in italics. Clinicopathologic informa
adenocarcinoma; COAD, colon adenocarcinoma; MEL, melanoma
mutations (see Table W10). Detailed OCP RNA-seq results, including 3
cancers are shown in Figure 3B. (B) Integrative OCP results from two
gene fusions. Copy number plots show log2 copy number ratios (co
individual amplicon represented by a single dot and individual genes i
shown as black bars. By OCP, MO-17 (top), a BRAF wild-type melan
loss, TP53 R158L mutation, and a novel ERC1:BRAF gene fusion. OCP
by clinical testing, identified an FBXW7 L647fs mutation and a TPR:NT
reads and the variant allele frequency are shown. (C) Validation of OCP
12 fused to BRAF exon 9 (E12B9, blue) or 10 (E12B10, cyan)] and TP
qRT-PCR was performed on MO-17, MO-35, and five control MO sa
(normalized to the arithmetic mean of glyceraldehyde-3-phosphate d
calibrated to the mean of the MO control samples) + SD of triplica
TPR:NTRK1 was present in any sample other than that identified by Oco-isolation after macrodissection, with an overall average of 52%
estimated post-dissection tumor content per sample (range 5%-90%), as
assessed by histology (Tables S2–S4). Across the MO, LU, and PR
cohorts, we isolated an average of 1.3/2.8 μg, 2.0/3.3 μg, and 2.2/6.7 μg
of DNA/RNA per sample, respectively. Overall, 32% of the FFPE
specimens were at least 3 years old (average 2 years, rangeb1 to 10 years).
Multiplexed PCR-based DNA and RNA libraries were generated
from each sample for template preparation andNGS on the IonTorrent
PGM using Ion 318 chips. We excluded DNA and RNA libraries from
1/105 MO, 3/104 LU, and 2/118 PR samples due to low-quality
libraries, resulting in a total of 321/327 (98%) informative samples. An
additional two samples (MO-46 and LU-141) were excluded from
CNA analysis due to excessively noisy copy number profiles (Figure S1).
Across the three cohorts, using the DNA panel, we achieved an average
of 5,142,690 mapped reads (97% on-target), 1941× coverage across
targeted bases, 93.6% of targeted bases covered by at least 20 reads, and
202 called variants per informative sample. Using the RNA panel, we
achieved an average of 306,872 total mapped reads (including 210,712
reads mapped to the five housekeeping/positive expression genes) per
sample. Complete sequencing statistics are provided in Tables S2 to S4,
with all called DNA variants, including splice site alterations, given in
Table S9. All high-level OCP-prioritized (see Materials and Methods
sections) CNAs and gene fusions across the cohorts are given in Tables
S10 and S11, respectively.
OCP Validation in a Clinical Molecular Diagnostics Cohort
To validate the performance of the OCP and identify additional
relevant variants beyond current routine practice, we assessed a cohort
of 105 FFPE cancer samples sent for molecular testing for EGFR,
BRAF, KRAS, and ALK alterations in a Clinical Laboratories
Improvement Amendments/College of American Pathologists–certi-
fied molecular diagnostics laboratory. The 104 informative MO
samples from 104 patients were composed of colorectal adenocarci-
nomas (n = 29), lung adenocarcinomas (n = 23), melanomas (n = 48),
and four other cancers (see Table S2). After filtering to the predefined
Oncomine variants, we identified an average of 1.7, 0.8, and 1.7
relevant somatic point mutations, indels, and high-level CNAs,
respectively, per sample. Genes most frequently harboring relevant
alterations across the MO cohort were TP53 (33%), BRAF (31%),ing molecular diagnostics testing. (A) We applied the OCP to a
olecular diagnostics testing for somatic mutations in BRAF, KRAS or
lterations from the RNA (in the header) and DNA components of the
cific alteration types are indicated according to the legend (Nonsyn.
frame-preserving indels, respectively). Slashed boxes indicate two
ed as in the legend. Samples excluded from copy number analysis
tion is given in the header according to the legend (LUAD, lung
); 100% concordance with molecular testing was observed for
′/5′ expression imbalance, for the ALK rearrangement–positive lung
cases, MO-17 and MO-25 (names bolded in A) harboring relevant
mpared to a composite normal sample) per amplicon, with each
ndicated by different colors. Gene-level copy number estimates are
oma by clinical testing, harbored CDKN2A high-level copy number
profiling of MO-35, a KRAS/BRAFwild-type colon adenocarcinoma
RK1 gene fusion. For mutations, variant allele containing reads/total
identified gene fusions using qRT-PCR for ERC1:BRAF [ERC1 exon
R:NTRK1 [TPR exon 21 fused to NTRK1 exon 10 (T21N10, orange)].
mples without OCP-detected gene fusions. Mean log2 expression
ehydrogenase (GAPDH) + hydroxymethylbilane synthase (HMBS)
te qPCRs is plotted. No detectable expression of ERC1:BRAF or
CP.
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across the MO cohort is shown in Figure 2A, and copy number
profiles for all samples are shown in Figure S3.
A total of four prioritized gene fusions was identified across the
cohort: EML4:ALK in two lung cancer samples positive for ALK
rearrangement by molecular testing (MO-100 and MO-106),
ERC1:BRAF in a melanoma sample (MO-17), and TPR:NTRK1 in
a colon cancer sample (MO-35; Figure 2, A and B). Importantly,multiple isoforms of the ERC1:BRAF fusion were identified in
MO-17 due to combinatorial priming/amplification, including
fusions of ERC1 and BRAF exons 17 to 8 (designated as E17B8),
12 to 9 (E12B9), and 12 to 10 (E12B10), respectively. qRT-PCR
confirmed expression of ERC1:BRAF and TPR:NTRK1 fusions in
MO-17 and MO-35, respectively (Figure 2C).
The 104 informative MO samples underwent 129 total molecular
diagnostic tests for EGFR, BRAF, KRAS, and ALK alterations. The
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44, 100%) and specificity (61 of 61, 100%) for detecting the
clinically identified EGFR, BRAF, and KRAS mutations (Figure 2A
and Table S12). Likewise, as described above, the RNA component of
the OCP detected gene fusions involving ALK in two of the three
(66%) samples with ALK rearrangements by fluorescence in situ
hybridization (FISH) testing in the molecular diagnostics laboratory.
In MO-66, a lung adenocarcinoma with an ALK rearrangement by
molecular testing, OCP profiling identified only nine EML4:ALK
fusion reads, which was below our threshold for calling a gene fusion
present; however, as described below, we observed 3′/5′ ALK
expression imbalance in this case (see Figure 3B). In total, considering
MO-66 as failing to detect the ALK rearrangement, the 129
molecular tests performed across the MO cohort involving integrative
DNA/RNA profiling by OCP showed 99.2% accuracy compared to
molecular diagnostic testing. Additional findings from the MO
cohort, including identification of relevant alterations not assessed by
molecular testing, are described below.
OCP Application in a Lung Cancer Cohort
We also applied theOCP to a retrospectively identified cohort of 104
primary lung tumors given the assessment of somatic variants in lung
cancer management [10]. The 101 informative samples from 96
individuals, which were chosen to represent the pathologic/histologic
spectrum, consisted of 69 adenocarcinomas, 21 squamous cell
carcinomas, 5 adenosquamous carcinomas, 2 bronchioloalveolar
carcinomas (1 adenocarcinoma in situ and 1 well-differentiated lepidic
predominant adenocarcinoma), 2 pulmonary small cell carcinomas
(SCCs), and 2 carcinoid tumors (Figure 3A and Table S3). After
filtering to the predefined Oncomine variants, we identified an average
of 1.2, 0.3, and 1.9 relevant somatic point mutations, indels, and
high-level CNAs, respectively, per sample. TP53 (38%), KRAS (28%),
and EGFR (24%) were the genes most frequent relevant alterations
across the LU cohort. Alteration frequencies varied between histologic
subtypes as expected. For example, high-level CNAs inNKX2-1, which
represent the most significant focal gain in lung adenocarcinoma [35],
were observed in 15 of 69 (22%) adenocarcinomas in our LU cohort
but were not observed in the 21 squamous cell carcinomas (P = .0083,
two-sided Fisher exact test). Of note, both SCCs harbored nonsense
RB1 mutations, while both carcinoid tumors lacked prioritized
alterations. An integrative heat map of prioritized alterations across
the LU cohort is shown in Figure 3A, and copy number profiles for all
LU samples are shown in Figure S4.
Fourteen samples in the LU cohort underwent successful
diagnostic molecular testing (as in the MO cohort) for EGFR and/
or ALK alterations (27 total tests). OCP demonstrated 100%
sensitivity and specificity for EGFR alterations in these samples; inFigure 3. OCP identified relevant somatic alterations, including gen
retrospective cohort of FFPE lung tumors selected to represent diver
the RNA (in header) and DNA components of the OCP for the 101 i
information is given in the header according to the legend [Met, met
carcinoma; BAC, bronchioloalveolar carcinoma (adenocarcinoma in
SCC, small cell carcinoma; Resect., resection; Bx, biopsy]. All 101 info
excluded from copy number analysis due to noisy profiles are shown i
gene fusion partners, OCP includes 5′ and 3′ amplicons for ALK, ROS
fusions. For all lung tumors (including those from the MO cohort), n
(red) and ROS1 (green) is plotted. No fusions involving RET were dete
(top panel) and ROS1 (middle panel) for each sample is plotted. ALK
(gray) samples by molecular testing are indicated.LU-49, two somatic EGFR hotspot GoF mutations that were not
assayed for through molecular testing were identified by OCP
(p.S768I, 37% variant allele frequency; p.G719C, 35% variant allele
frequency). All three samples with EML4:ALK fusions by OCP
(LU-1, LU-30, and LU-150) harbored ALK rearrangements by
FISH. In addition, in LU-61, an adenocarcinoma lacking other
actionable alterations, we identified an EZR:ROS1 fusion (exon 10 of
EZR fused to exon 34 of ROS1). As shown in Figure 3B, all LU
samples with detectable ALK and ROS1 fusions by targeted RNA-seq,
as well as MO-100 and MO-106 (EML4:ALK fusion positive as
described above), showed 3′/5′ expression imbalance in the involved
3′ partner. In total, across the LU and MO cohorts, six of the eight
(75%) samples with the greatest 3′/5′ ALK expression imbalance by
OCP harbored ALK rearrangements by FISH (Figure 3B), supporting
the complementary information provided by this approach. Addi-
tional assessment of OCP performance in cases with known gene
fusions is provided in the PR cohort below.
OCP Validation and Application in a Prostate Cancer Cohort
Lastly, we applied the OCP to a cohort of 118 retrospectively
identified prostate cancers for validation and application. The PR
cohort was selected to enrich for samples poorly represented in
standard frozen tissue cohorts, with the 116 informative samples
(from 114 patients) including 35 diagnostic biopsy samples, 20
samples from individuals ≤55 years of age, and 50 previously treated
samples (Figure 4A and Table S4). After filtering to the predefined
Oncomine variants, we identified an average of 1.0, 0.2, and 1.2
relevant somatic point mutations, indels, and high-level CNAs,
respectively, per sample. Besides T2:ERG gene fusions (see below),
the genes most frequently harboring relevant alterations in the PR
cohort were TP53 (27%), PTEN (18%), and ATM (11%). An
integrative heat map of prioritized alterations across the PR cohort is
shown in Figure 4A, and copy number profiles for all PR samples are
shown in Figure S5.
Approximately 40% to 60% of prostate cancers harbor recurrent
gene fusions, typically involving 5′ androgen–regulated genes fused to
3′ ETS transcription factor family members, with the most common
fusion being TMPRSS2(T2):ERG [36,37]. The RNA component of
the OCP is designed to detect recurrent gene fusions in prostate
cancer through inclusion of forward primers in known 5′ fusion
partners (including TMPRSS2, SLC45A3, and C150RF21) and
reverse primers in known 3′ fusion partners (including ERG, ETV1,
ETV4, and BRAF). Across the PR samples, OCP detected ETS gene
fusions in 58 of 100 (58%) samples, as shown in Figure 4B. Of note,
among the 54 T2:ERG fusion–positive samples, we identified a
median of three unique fusion isoforms (range 1-9) due to
combinatorial priming allowed by targeted RNA-seq, consistente fusions, in a lung cancer cohort. (A) We applied the OCP to a
se pathology (LU cohort). All OCP defined relevant alterations from
nformative samples are shown in the heat map. Clinicopathologic
astasis; LUSQ, squamous cell carcinoma; ADSQ, adenosquamous
situ or well-differentiated lepidic predominant adenocarcinoma);
rmative lung samples were included in OCP RNA analysis. Samples
n italics. (B) In addition to primers for pan-cancer prioritized 5′ and 3′
1, and RET to identify 3′/5′ expression imbalance indicative of gene
ormalized OCP RNA-seq expression of gene fusions involving ALK
cted. Corresponding normalized 3′/5′ expression imbalance for ALK
rearrangement positive (bolded red), negative (blue), or untested
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fusion-positive tumors, including those reported to drive aggressive
disease [38].
Thirty-seven informative PR samples were previously assessed
using an integrative DNA/RNA molecular profiling assay (MiPC)
based on Haloplex target capture and Ion Torrent NGS coupled with
qRT-PCR [30], providing an opportunity for additional OCPvalidation. Using automated variant calling and filtering, OCP
profiling demonstrated 97% sensitivity (29 of 30) for detecting
commonly targeted somatic variants (from 37 samples assessed by
both approaches) with highly concordant observed variant allele
frequencies (Table S13). High-level CNAs in 34 genes targeted by
both OCP and MiPC were also strongly correlated (Pearson r: 0.95;
P b .001, [30]).
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RNA component of MiPC, which used a validated TaqMan qRT-PCR
assay for T2:ERG (exon 1 of TMPRSS2 fused to exon 4 of ERG,
designated as T1E4) and 3′ TaqMan expression assays for ERG, ETV1,
ETV4, and ETV5 expression [30], with outlier expression of these genes
indicative of gene fusions.We observed 100% concordance forT2:ERG
isoform T1E4 expression by OCP andMiPC (Figure 4B). Importantly,
in the three cases identified as ERG expression outliers (without
T2:ERG isoform T1E4 expression) by MiPC, we identified an
SLC45A3:ERG gene fusion in PR-23 (three detected fusion isoforms)
and expression of non-T1E4 T2:ERG isoforms in PR-30 and PR-57
(PR-57 had T2:ERG T1E4 fusion reads detectable at b1/10,000th of
non-T1E4 reads). Additionally, by OCP, we detected a
TMPRSS2:ETV1 gene fusion (supported by three fusion isoforms) in
one of the four samples with ETV1 outlier expression by MiPC
(PR-7-3). No fusions were detected involving ETV4 or ETV5 in the PR
cohort, although 2 of the 37 samples profiled previously by MiPC
harbored ETV4 or ETV5 outlier expression, consistent with fusions
involving 5′ partners not targeted by the OCP. Taken together, with
results from the MO and LU cohorts described above, these results
support the ability of targeted RNA-seq to identify isoform-specific
gene fusions through combinatorial priming and suggest that inclusion
of 5′/3′ expression amplicons (as for lung fusions) may improve
detection of fusions involving novel 5′ partners.
The inclusion of a large number of treated samples in the PR cohort
enabled comparisons related to treatment status and unique histology/
immunophenotype post-treatment (i.e., prostatic neuroendocrine/SCC
and samples with no/low canonical ardrogen receptor (AR) signaling by
IHC [AR−]). For example, although TP53 was the most frequently
altered gene (besides ERG) in the PR cohort, TP53 alteration frequency
varied significantly across sample types, from 8.4% (6 of 71) of
untreated or single modality treated samples [androgen deprivation
(ADT) or radiation therapy (XRT)] to 100% of prostatic SCC (Table
S14, P b .001). Likewise, ATM alteration frequency varied across
treatment subtypes, with 7 of 22 (32%) of samples treated with ADT +
XRT and/or chemotherapy [ADT+] harboring ATM alterations
compared to 0 of 8 (0%) of SCCs (Table S15, P = .14). Robust
prostate cancer molecular subtypes have been identified, including
those defined by ETS gene fusions, SPOP hotspot mutations, and rare
alterations (i.e., fibroblast growth factor receptor [FGFR] or RAF family
fusions) [36]. Of interest, PR-122 harbored an IDH1 R132 hotspot
mutation (at 18% variant allele frequency) but lacked ETS gene fusions,
SPOPmutations, or other prioritized alterations (Figures 4A and S6A).
Assessment of the current PR cohort combined with 353 prostate
cancer samples in the cBioPortal database identified IDH1 R132Figure 4. Application ofOCP to a prostate cancer cohort identifies variab
isoform-specific gene fusion detection. (A) We applied the OCP to
OCP-defined relevant alterations from theRNA (in the header) andDNA
the heat map. Clinicopathologic information is given in the header acco
nodemetastasis; PRAD, prostatic adenocarcinoma; SCC, small cell car
For treatment subtype, ADT = prior androgen deprivation therapy, XRT
AR− = no (or reduced) AR signaling as indicated by no/focal prost
sequenced in OCP RNA analysis are indicated as in the legend. (B) The
fusion partners and reverse primers in known 3′ fusion partners for recur
indicated gene fusion isoforms are indicated in each cell according to
(right) and fusion isoformsnamedby the exon junctionsof the involved g
1 and ERG exon 4). qRT-PCRwas previously performed on a subset of t
low expression), and ERG outlier expression without T1E4 isoform d
indicated in the header. Samples without any of these alterations (Negmutations in 6/453 (1%) prostate cancers, all of which lacked ETS gene
fusions or SPOPmutations (P = .004, Fisher exact test; Figure S6B and
Table S16), supporting IDH1 mutations as defining a unique prostate
cancer molecular subtype.
Lastly, OCP allowed us to assess paired samples that can inform on
molecular correlates of disease progression, which is particularly
challenging in prostate cancer given the long follow-up typically
required to obtain sequential progressive specimens and the lack of
routine biopsy confirmation of metastatic disease. In the PR cohort,
PR-77 represents a primary, untreated Gleason score 9, pT3b N0
prostatectomy sample, while PR-88 is a paired urinary bladder tumor
resected 4 years later after ADT, XRT, and docetaxel chemotherapy
with AR− phenotype. Both samples showed focal prioritized MCL1
and MYC amplifications (and non-prioritized high-level BRCA1
amplification), consistent with clonality; however, a TMPRSS2:ERG
fusion (exon T2E2) was identified by the OCP RNA-seq panel
exclusively in PR-77, consistent with the AR− phenotype in PR-88
(Figure S7A). In contrast, PR-88, the AR− metastasis, uniquely
harbored prioritized AR amplification and CDKN2A deletion, as well
as a CTNNB1 (β-catenin) GoF mutation (S37C, variant allele
frequency 10%). Of note, no read support for CTNNB1 S37C was
present in PR-77, despite N5000 covering reads. Likewise, PR-160, a
post-therapy (ADT + chemotherapy) epidural metastasis resected
after rapid progression in a man who presented with metastatic disease
at the age of 49, harbored a focal, prioritized CTNNB1 amplification,
which was not present in a pre-treatment, diagnostic prostate biopsy
specimen that shared other clonal alterations with PR-160 (Figure
S7B). These results demonstrate the utility of OCP for identifying
alterations associated with treatment resistance through profiling
pre-treatment/post-treatment limiting FFPE specimens.
Actionability Assessment
An important component of the OCP is a knowledge base of
therapies and clinical trials associated with the predefined potential
actionable variants targeted by the NGS assay. Potential therapeutic
strategy prioritization for each OCP assessed sample is based on
histologic cancer type and level of evidence associated with the
potential actionability of each variant (FDA-approved agent, within
cancer-type NCCN guideline, outside cancer-type NCCN guideline,
and biomarker directed/informed clinical trials; see Table S5). In
cases with multiple potential actionable variants, potential treatment
strategies are prioritized, including consideration of detected variants
that preclude treatment strategies based on other identified variants
(i.e., KRASmutations and potential EGFR inhibitor–based treatment
in colorectal adenocarcinoma).le alterations across histologic and treatment subtypes and confirms
a retrospective cohort of aggressive FFPE prostate cancers. All
components of theOCP for the 116 informative samples are shown in
rding to the legend (Met, metastasis; Pros., prostate; LNmet, lymph
cinoma; SQ, squamous differentiation; RRP, radical prostatectomy).
= radiation therapy, ADT+ = ADT plus XRT and/or chemotherapy,
ate specific antigen (PSA) staining. Samples excluded from or not
RNA component of the OCP contains forward primers in known 5′
rent gene fusions in prostate cancer. Normalized log2 read counts for
the color scale, with individual fusions indicated by the color blocks
enes (e.g., T2:ERG T1E4 indicates a fusion junction of TMPRSS2exon
hese cases, as indicated in qPCR type. T2:ERG T1E4 status (including
etection (ERG+), ETV1 (ETV1+), ETV4 (ETV4+), or ETV5 (ETV5+) are
) or not tested (N/A) by qPCR are indicated.
AB
Figure 5. Automated treatment prioritization by OCP identifies relevant alterations beyond routine molecular testing. (A) For each OCP
assessed cohort, the breakdown of the highest prioritized alteration per sample is shown, according to whether the alteration is
associated with 1) FDA-approved therapies (red), 2) therapies within NCCN indications (orange), 3) therapies outside that specific cancer
type’s NCCN indication (yellow), or 4) clinical trial entry requirements (blue). This assessment incorporates variants precluding treatment
strategies based on other identified variants but does not prioritize variants that only exclude approved agents. Individual prioritized
alterations are indicated as slices of each pie and are shown in the histogram. (B) Integrative OCP profiling prioritized high-level ERBB2
copy gains in two lung carcinomas. Integrative OCP results are shown as in Figure 2B (gene fusions were not identified in either sample).
OCP profiling prioritized high-level ERBB2 copy number gains in MO-65 (top), an EGFR/ALK wild-type lung adenocarcinoma by diagnostic
molecular testing, and LU-31 (bottom), a lung SCC with no previous molecular diagnostic testing. Morphology by hematoxylin and eosin
staining is shown (inset of LU-31 shows typical small cell morphology). Diffuse 3+ ERBB2 protein expression was confirmed by IHC.
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options, we identified the highest priority alteration for each sample
assessed herein, as shown in Figure 5A. These analyses only includepositively associated variants (i.e., KRAS mutations in colorectal
cancer excluding EGFR inhibitors are not prioritized). In the MO
cohort, OCP confirmed the presence of BRAF, EGFR, and ALK
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indications. In an additional 15 MO samples (14%), OCP identified
an actionable variant that is not routinely tested for in that cancer type
but which is associated with the same (n = 2) or other cancer type (n =
13) approved therapies referenced in NCCN clinical guidelines (e.g.,
ERBB2, BRAF, and EGFR alterations). These findings are especially
important because emerging evidence supports benefit, in some cases
substantial, to an available targeted therapy. For example, responses to
the BRAF inhibitor dabrafenib in lung cancer patients with BRAF
mutations in a phase II trial led to Breakthrough Therapy designation
by the FDA, and combination trials with the mitogen activated
protein kinase kinase (MEK) inhibitor trametinib—which proved
superior to single-agent BRAF therapy in melanoma [39,40]—are
enrolling. An additional 44 samples (42%) harbored alterations in a
gene that is a positive eligibility criterion for a clinical trial involving a
targeted therapy (e.g., PIK3CA, NRAS, and so on).
Likewise, in the LU cohort, OCP identified alterations associated
with FDA-approved therapies, NCCN guidelines, and clinical trial
eligibility in 21 (21%), 15 (15%; n = 11 same cancer; n = 4 other
cancer), and 52 (51%) samples, respectively. Lastly, in the PR cohort,
OCP identified alterations associated with FDA-approved therapies,
NCCN guidelines, and clinical trial eligibility in 0 (0%), 7 (6%; all
other cancers), and 42 (36%) samples, respectively, demonstrating
that “actionable” alterations occur with variable frequency across
cancers from different organs. As an example of a highly actionable
alteration that is not routinely tested for in the specific cancer type
(lung cancer) nor assessed by targeted NGS approaches that do not
assess CNAs, OCP prioritized high-level gains in ERBB2 in MO-86
and LU-31 (lung adenocarcinoma and lung SCC, respectively), with
overexpression in both cases confirmed by IHC (Figure 5B).
Discussion
Here, we report the development, validation, and assessment of a
highly scalable, FFPE-compatible, targeted NGS-based system to
prioritize potential treatment strategies from predefined relevant
somatic variants in solid tumors. To identify candidate driving
somatic alterations for inclusion in the OCP, we queried genomic
data from more than 700,000 tumor samples to define pan-solid
tumor, recurrent driving somatic alterations through defining GoF
mutations in oncogenes, LoF (and GoF) mutations in tumor
suppressors, CNAs through MCR analysis, and recurrent gene
fusions. These alterations were combined with a comprehensive
knowledge base of currently available oncology therapeutics and
clinical trials to define variants with immediate or near-term
relevance. We then developed a targeted multiplexed PCR-based
NGS panel compatible with limited amounts of routine FFPE tissue
samples (20 ng of DNA/15 ng of RNA) to detect these variants.
These nucleic acid requirements are 2- to 50-fold less than those for
comprehensive capture-based precision oncology approaches [18,21].
To balance OCP panel size and clinical relevance, we excluded genes
without near-term clinical actionability and only currently identified
hotspots are targeted. Hence, additional genes/amplicons may be
included in future OCP versions or supplemental panels to target
novel relevant alterations, including treatment resistance hotspots
poorly represented in most publically available profiling studies.
We validated OCP performance using more than 300 FFPE tumor
specimens, including a prospective cohort of 104 samples undergoing
concurrent molecular diagnostics testing for BRAF, KRAS, or EGFR
point mutations and indels, achieving a sensitivity and specificity of100%. We and others have previously validated the utility of
multiplexed PCR-based Ion Torrent sequencing for CNA assessment
[19,25,31–33] and herein confirm high-level ERBB2 CNAs
identified by OCP using IHC. OCP identified mutations and
high-level CNAs were also highly concordant with results from
Haloplex capture-based NGS in a subset of the PR cohort profiled by
both technologies. Taken together, these results demonstrate the
ability of OCP to identify these relevant classes of alterations.
Frame-shifting indels in long homopolymer runs are challenging to
detect with current Ion Torrent approaches (and are excluded using
our filtering criteria) and multiplexed PCR approaches cannot detect
large structural rearrangements; however, these alterations predom-
inantly result in LoF alterations in tumor suppressors [41], which
represent a minority of current therapeutic targets. We anticipate that
our cohort and additional OCP profiled samples will enable the
development of panel- and laboratory-specific error models to
improve performance in homopolymer regions.
The RNA component of the OCP is designed to identify known
recurrent gene fusions (through primers spanning known exon
junctions) as well as fusions of RET, ROS1, and ALK with novel 5′
partners (or novel fusion isoforms) through 3′/5′ expression
imbalance. We confirmed 100% concordance for T2:ERG gene
fusion isoform-specific detection between OCP and a validated
quantitative PCR (qPCR) assay in a subset of our PR cohort profiled
by both methods, with multiple splice variants detected in the
majority of fusion-positive cases. Likewise, in seven lung cancers
known to harbor ALK rearrangements across our cohorts, OCP
profiling identified EML4:ALK fusions in five (71%), with these five
samples also showing 3′/5′ expression imbalance by OCP. MO-66
(the known ALK rearranged sample with fusion read support below
our threshold criteria) and LU-38 (known ALK rearrangement
without fusion read support) also showed 3′/5′ expression imbalance.
Of note, in our MO cohort, we identified two additional relevant
fusions [ERC1:BRAF in a melanoma sample negative for BRAF
mutation (MO-17) and TPR:NTRK1 in a colon cancer (MO-35)],
validating both fusions by qPCR. Of note, ERC1:BRAF was not
directly targeted in the OCP RNA panel design, as ERC1 had
previously only been reported as a fusion partner with RET [42],
highlighting the utility of the combinatorial nature of targeted
multiplexed PCR-based RNA-seq.
Taken together, our results validate the multiplexed PCR-based
RNA-seq approach for detecting targeted gene fusions. Characterization
of additional cohorts will be required to determine performance and
optimal 3′/5′ expression imbalance cutoffs for ALK, RET, and ROS1
fusions in lung cancer (and other cancer types) involving unknown
partners. Likewise, we anticipate that inclusion of additional 3′/5′
expression imbalance amplicons will improve fusion detection involving
other genes. Lastly, splice variant detection of non-gene fusion events,
such as AR splice variants in prostate cancer [43,44] or alternatively
spliced tyrosine kinases (e.g.,MET) in other cancers [45,46], may also
be assessed in OCP through inclusion of additional amplicons.
Importantly, although comprehensive capture-based NGS approaches
assessing only DNA can identify gene fusions through sequencing
introns of involved genes [18], such approaches cannot detect or
quantify potentially relevant splice variants.
As a demonstration of the utility of OCP for translational research,
we applied this approach to a cohort of 116 prostate cancers,
including 50 previously treated samples. We recapitulated known
molecular subtypes and alterations with specific histology, including
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We also identified a high burden of ATM alterations in heavily
treated patients, which can be investigated in future efforts
characterizing this understudied population. Of note, through
integration with previous profiling studies, we identify IDH1 R132
mutant prostate cancer as a novel molecular subtype that lacks other
subtype defining lesions. This finding is especially important as IDH1
inhibitors are now in early phase clinical trials. Lastly, two pairs of
pre-treatment and post-treatment samples each demonstrated AR
amplifications (a known adaptive response to ADT [53]) and
CTNNB1 GoF mutation/amplification exclusively in the post-treat-
ment sample. Although activation of the WNT/CTNNB1 pathway
has been identified in ADT-treated prostate cancer [29,54,55], our
report is the first to demonstrate that ADT and/or subsequent
chemotherapy specifically induces (or selects) for CTNNB1 ampli-
fication/activating mutation, supporting a functional role in
treatment resistance.
The OCP is compatible with routine Ion Torrent workflows, and
the DNA/RNA components of the OCP can be combined for
template preparation and concurrent PGM sequencing on a single
Ion Torrent 318 chip in a standard ~4 hour PGM run, with the
potential for higher throughput using the Ion Torrent Proton.
Although complete analytic validation will need to be performed in
individual laboratories, we demonstrate highly concordant results
with typical specimens sent for molecular diagnostic testing as well as
molecular standards (performance with downsampled reads is shown
in Figure S8). Hence, this approach provides a rapid, highly scalable
approach requiring small amounts of routine tissue specimens with
performance comparable to previous multiplexed PCR-based Ion
Torrent panels assessing DNA alterations [16,19,22], capture-based
approaches[18,56], and anchored multiplexed PCR-based NGS [24].
A critical component of the OCP is a highly automated analysis
pipeline that links to a knowledge base of potential treatment options,
facilitated by predefining the actionable cancer genome before panel
development. As shown through our actionability assessment, a
significant number of samples currently harbor relevant alterations
that are identifiable using our approach. As clinical sequencing efforts
and expertise become more prevalent, a key advantage of the OCP is
the potential for integration into multiple independent institutions
(rather than a single centralized testing center), enabling valuable
direct involvement from molecular biologists, pathologists, and
oncologists. Taken together, the highly scalable assay and framework
described herein may have utility in future oncology precision
medicine approaches, such as the NCI Match Trial, where multiple
sites will sequence 3000 cancer samples using the OCP.
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